These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 12479366)

  • 1. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
    Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Clark AS; West K; Streicher S; Dennis PA
    Mol Cancer Ther; 2002 Jul; 1(9):707-17. PubMed ID: 12479367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.
    Dufourny B; Alblas J; van Teeffelen HA; van Schaik FM; van der Burg B; Steenbergh PH; Sussenbach JS
    J Biol Chem; 1997 Dec; 272(49):31163-71. PubMed ID: 9388270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
    Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
    Kilker RL; Planas-Silva MD
    Cancer Res; 2006 Dec; 66(23):11478-84. PubMed ID: 17145896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
    Mirza AM; Gysin S; Malek N; Nakayama K; Roberts JM; McMahon M
    Mol Cell Biol; 2004 Dec; 24(24):10868-81. PubMed ID: 15572689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining flavopiridol with various signal transduction inhibitors.
    Witters LM; Myers A; Lipton A
    Oncol Rep; 2004 Mar; 11(3):693-8. PubMed ID: 14767524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.
    Nahta R; Iglehart JD; Kempkes B; Schmidt EV
    Cancer Res; 2002 Apr; 62(8):2267-71. PubMed ID: 11956082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
    Carlson B; Lahusen T; Singh S; Loaiza-Perez A; Worland PJ; Pestell R; Albanese C; Sausville EA; Senderowicz AM
    Cancer Res; 1999 Sep; 59(18):4634-41. PubMed ID: 10493518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells.
    Sheng H; Shao J; DuBois RN
    J Biol Chem; 2001 Apr; 276(17):14498-504. PubMed ID: 11278613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells.
    Lee AW; Nambirajan S; Moffat JG
    Oncogene; 1999 Dec; 18(52):7477-94. PubMed ID: 10602507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
    Nahta R; Trent S; Yang C; Schmidt EV
    Cancer Res; 2003 Jul; 63(13):3626-31. PubMed ID: 12839951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.